SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC - INTRA CELLULAR THERAPIES INC ownership

INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 265 filers reported holding INTRA CELLULAR THERAPIES INC in Q2 2022. The put-call ratio across all filers is 0.88 and the average weighting 0.3%.

Quarter-by-quarter ownership
SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC ownership history of INTRA CELLULAR THERAPIES INC
ValueSharesWeighting
Q2 2023$5,351,490
+95.4%
84,515
+67.1%
0.20%
+76.8%
Q1 2023$2,739,394
-65.3%
50,589
-63.4%
0.11%
-68.5%
Q2 2022$7,896,000
-46.2%
138,331
-42.3%
0.36%
-32.0%
Q1 2022$14,680,000239,9030.52%
Other shareholders
INTRA CELLULAR THERAPIES INC shareholders Q2 2022
NameSharesValueWeighting ↓
TANG CAPITAL MANAGEMENT LLC 700,000$42,833,0008.57%
SILVERARC CAPITAL MANAGEMENT, LLC 308,819$18,897,0007.82%
Vahanian & Associates Financial Planning Inc. 45,533$2,786,0006.44%
DCF Advisers, LLC 238,500$14,594,0006.39%
INTERNATIONAL BIOTECHNOLOGY TRUST PLC 50,956$20,930,0004.72%
SUVRETTA CAPITAL MANAGEMENT, LLC 1,531,923$93,738,0002.86%
Nicholas Investment Partners, LP 562,373$34,412,0002.45%
Bellevue Group AG 3,429,619$209,859,0002.44%
WASATCH ADVISORS LP 7,477,868$457,571,0002.25%
Quantum Private Wealth, LLC 73,772$4,514,0001.95%
View complete list of INTRA CELLULAR THERAPIES INC shareholders